|
|
|
| Clinical effect of Fuzheng Huayu Capsules combined with Entecavir in the treatment of liver cirrhosis of hepatitis B |
| ZHANG Sheng-yu1 ZHOU Fu-cheng2 NIU Yu-lan2 WU Qian2
|
1.Suqian Nursing School of Jiangsu Province,Suqian 223800,Chna;
2.Department of Infection,Zhongwu Hospital of Suqian City,Jiangsu Province,Suqian 223800,China |
|
|
|
|
Abstract ObjectiveTo investigate the clinical effect of Fuzheng Huayu Capsules combined with Entecavir in the treatment of liver cirrhosis of hepatitis B.MethodsFrom January 2013 to December 2016,120 patients with liver cirrhosis of hepatitis B treated in Zhongwu Hospital of Suqian City were selected and they were divided into the observation group(n=60)and control group(n=60)in random.The Compound Glycyrrhizin,Reduced Glutathione,liver protection,and enzyme decrease were provided in both groups.In the control group,oral administration of Entecavir Dispersible Tablets was applied,0.5 mg each time,once a day.In the observation group,Fuzheng Huayu Capsules for oral administration was adopted,0.2 g each time,3 times per day.Alanine transaminase(ALT),aspartate aminotransferase(AST),albumin(Alb),total bilirubin(TBil),Child-Pugh score,HBV-DNA quantitative,laminin(LN),Ⅳ-collagen(Ⅳ-C),hyaluronic acid(HA),mean flow velocity of main portal vein(v),and internal diameter of portal vein(D)were compared and observed in the two groups before and after 6 months treatment.ResultsAfter treatment,ALT,AST,Alb,TBil,LN,Ⅳ-C,HA,Child-Push score,and HBV-DNA quantitative were significantly better than those before treatment(P＜0.05).Alb,Child-Pugh score,LN,Ⅳ-C,and HA in the observation group were all better than those in the control group after therapy(P＜0.05).There was no great difference in improvement of mean flow velocity of main portal vein(v),and internal diameter of portal vein(D)in the control group compared with that before(P＞0.05).In the observation group,the improvement of mean flow velocity of main portal vein(v)was better than that before with a statistical difference.Meanwhile,internal diameter of portal vein(D)in the observation group after therapy was greatly improved but without statistical significance(P＞0.05).ConclusionEntecavir treating liver cirrhosis of hepatitis B can swiftly inhibit viral replication and decrease the amount of hepatitis B virus in peripheral blood,and restore the liver function to normal.Entecavir combined with Fuzheng Huayu Capsules can reduce Child-Pugh score,increase Alb level,and improve liver fibrosis indexes and portal vein hemodynamics.
|
|
|
|
|
|
| [2] |
中华医学会肝病学分会，中华医学会感染病学分会.中国慢性乙型肝炎防治指南（2015年版）[J].中国肝脏病杂志（电子版），2015，7（3）:1-18.
|
| [3] |
中华医学会肝病学分会.乙肝相关肝硬化诊疗规范专家共识（2014 版）[J].中华消化杂志，2014，34（2）:221-223.
|
| [4] |
科技部十二五重大专项联合课题组.乙型肝炎病毒相关肝硬化的临床诊断、评估和抗病毒治疗的综合管理[J].中华肝脏病杂志，2014，22（3）:327-335.
|
| [5] |
闫宏，宁福军.恩替卡韦诊疗乙肝肝硬化合并肝源性糖尿病的临床效果分析[J].中国当代医药，2016，23（12）:107-109.
|
| [6] |
王秀珍，刘雪峰.2041例肝硬化病因及并发症分析[J].浙江医学，2017，39（1）:37-39.
|
| [1] |
Liang X，Bi S，Yang W，et al.Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination[J].Vaccine，2009，27（47）:6550-6557.
|
| [7] |
张洁，周振华，孙学华，等.单核巨噬细胞与乙型肝炎病毒感染的研究进展[J].中西医结合肝病杂志，2017，27（3）:185-189.
|
| [8] |
刘慧，鲁凤民.HBx蛋白与宿主胞内蛋白相互作用对增强HBV 复制的研究进展[J].肝癌电子杂志，2016，3（2）:11-15.
|
| [9] |
吴江华.SB-525334对肝星状细胞胶原分泌和microRNA表达的影响[D].石家庄:河北医科大学，2016.
|
| [10] |
孙国战.乙肝患者肝癌患病风险及其预防分析[J].医学理论与实践，2015，28（2）:203-204.
|
| [11] |
张云涛，孟明星，李焱等.恩替卡韦和干扰素在慢性乙型肝炎抗病毒治疗中的应用[J].实用临床医药杂志，2015，19（7）:127-128.
|
| [12] |
李想.乙肝肝硬化并发原发性肝癌的危险因素分析[J].临床医学，2015，35（10）:48-50.
|
| [13] |
郎静，赵龙凤，许翠萍.恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的临床疗效分析[J].中国现代医生，2015，53（14）:71-73.
|
| [14] |
杨智娟.恩替卡韦联合扶正化瘀胶囊治疗乙肝肝硬化失代偿期的临床观察[J].当代医学，2015，22（17）:132-133.
|
| [15] |
毕玉珍.扶正化瘀胶囊联合恩替卡韦治疗乙肝肝硬化的临床疗效[J].数理医药学杂志，2016，29（5）:720-721.
|
| [16] |
王清兰，陶艳艳，沈丽，等.扶正化瘀方影响转化生长因子β1/Smad信号通路的抗肝纤维化作用机制[J].中西医结合学报，2012，10（5）:561-568.
|
| [17] |
郭小平.恩替卡韦联合扶正化瘀治疗肝硬化代偿期78例疗效观察[J].中国医刊，2016，51（12）:96-98.
|
| [18] |
赖江琼，刘国安，潘兴南，等.恩替卡韦联合扶正化瘀胶囊治疗64例乙型肝炎肝硬化超声表现及临床疗效分析[J].实用肝脏病杂志，2011，14（6）:488-489.
|
|
|
|
